Literature DB >> 11358804

Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice.

N Chen1, M Nomura, Q B She, W Y Ma, A M Bode, L Wang, R A Flavell, Z Dong.   

Abstract

Previous studies have shown that c-Jun NH(2)-terminal kinase (JNK) belongs to the mitogen-activated protein kinase (MAPK) family of signal transduction components that are rapidly initiated and activated by many extracellular stimuli. However, the potential role of JNK in mediating tumor promotion and carcinogenesis is unclear. We show here that in JNK2-deficient (Jnk2(-/-)) mice, the multiplicity of papillomas induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) was lower than that in wild-type mice. Papillomas on wild-type mice grew rapidly and were well vascularized compared with Jnk2(-/-) mice. After the 12th week of TPA treatment, the mean number of tumors per mouse was 4.13-4.86 in wild-type mice but only 1.13-2.5 in Jnk2(-/-) mice. TPA induced phosphorylation of extracellular signal-regulated kinases and activator protein-1 DNA binding activity in wild-type mice, but the phosphorylation of extracellular signal-regulated kinases and activator protein-1 DNA binding were inhibited in Jnk2(-/-) mice. These data suggest that JNK2 is critical in the tumor promotion process.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358804

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  76 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Loss of JNK2 increases intestinal tumor susceptibility in Apc1638+/- mice with dietary modulation.

Authors:  Xiuli Bi; Nicole M Pohl; Zhinan Yin; Wancai Yang
Journal:  Carcinogenesis       Date:  2010-12-23       Impact factor: 4.944

3.  Measuring the constitutive activation of c-Jun N-terminal kinase isoforms.

Authors:  Ryan T Nitta; Shawn S Badal; Albert J Wong
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

4.  Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation.

Authors:  Cristina Cellurale; Guadalupe Sabio; Norman J Kennedy; Madhumita Das; Marissa Barlow; Peter Sandy; Tyler Jacks; Roger J Davis
Journal:  Mol Cell Biol       Date:  2011-01-31       Impact factor: 4.272

5.  The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis.

Authors:  R T Nitta; C A Del Vecchio; A H Chu; S S Mitra; A K Godwin; A J Wong
Journal:  Oncogene       Date:  2010-09-27       Impact factor: 9.867

6.  The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.

Authors:  Hengning Ke; Rebecca Harris; Jonathan L Coloff; Jane Y Jin; Benjamin Leshin; Paula Miliani de Marval; Shiying Tao; Jeffrey C Rathmell; Russell P Hall; Jennifer Y Zhang
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

7.  Effects of MAP kinase inhibitors on epidermal growth factor-induced neoplastic transformation of human keratinocytes.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-01       Impact factor: 4.784

8.  The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer.

Authors:  Jennifer Y Zhang; Maria Angelica Selim
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm.

Authors:  Gayle Gordillo; Huiqing Fang; Savita Khanna; Justin Harper; Gary Phillips; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

10.  Targeted deletion of RasGRP1 impairs skin tumorigenesis.

Authors:  Amrish Sharma; Lauren L Fonseca; Cynthia Rajani; Jodi K Yanagida; Yuka Endo; J Mark Cline; James C Stone; Junfang Ji; Joe W Ramos; Patricia S Lorenzo
Journal:  Carcinogenesis       Date:  2014-01-24       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.